Financial support from 株式会社HGキャピタル
The Company (the filing company)
The company's group is in a period of upfront investment and continues to incur operating losses and negative operating cash flow. Improving its financial position and securing flexible financing are important challenges.
Gain on debt forgiveness of ¥400,000 thousand (extraordinary income). Total extraordinary income for the current consolidated fiscal year was ¥614,412 thousand.
Fiscal year ending March 2026 (1 April 2025 to 31 March 2026)
For the fiscal year ending March 2027, consolidated results are expected to be net sales of ¥750 million, operating income of ¥30 million, ordinary income of ¥20 million, and net income attributable to owners of the parent of ¥20 million.
Company response
① Research and development activities, ② transition to domestic production of products, ③ business expansion in new fields, ④ cost reductions, and ⑤ improvement of the financial position and implementation of financing
Sales of the Cell Therapy Kit began in February 2026, while the launch timing for the Cellution centrifuge has been revised to August 2026. During the fiscal year ending March 2027, the company is expected to enter the full-scale sales phase, while the Neocella business is expected to move into a revenue-generation phase through product supply and collaboration with partner institutions. The company will pursue the initiatives outlined above to improve profitability and strengthen its financial position.
| Item | Details |
|---|---|
| Event name | Financial support from 株式会社HGキャピタル |
| Date of occurrence | 27 March 2026 (the date on which 株式会社HGキャピタル offered financial support and the company decided to accept it) |
| Date recognized / date notice received | 27 March 2026 (the date on which the company received the offer of financial support) |
| Subject Entity | The Company (the filing company) |
| Cause | The company's group is in a period of upfront investment and continues to incur operating losses and negative operating cash flow. Improving its financial position and securing flexible financing are important challenges. |
| Amount of Impact on Business Performance | Gain on debt forgiveness of ¥400,000 thousand (extraordinary income). Total extraordinary income for the current consolidated fiscal year was ¥614,412 thousand. |
| Accounting period in which recognized | Fiscal year ending March 2026 (1 April 2025 to 31 March 2026) |
| Impact on Earnings Forecast | For the fiscal year ending March 2027, consolidated results are expected to be net sales of ¥750 million, operating income of ¥30 million, ordinary income of ¥20 million, and net income attributable to owners of the parent of ¥20 million. |
| Measures to prevent recurrence | ① Research and development activities, ② transition to domestic production of products, ③ business expansion in new fields, ④ cost reductions, and ⑤ improvement of the financial position and implementation of financing |
| Outlook | Sales of the Cell Therapy Kit began in February 2026, while the launch timing for the Cellution centrifuge has been revised to August 2026. During the fiscal year ending March 2027, the company is expected to enter the full-scale sales phase, while the Neocella business is expected to move into a revenue-generation phase through product supply and collaboration with partner institutions. The company will pursue the initiatives outlined above to improve profitability and strengthen its financial position. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.As a research and development-focused company, the company is in a period of upfront investment and continues to incur operating losses and negative operating cash flow. Improving its financial position and securing flexible financing are therefore important challenges. The company expects this support to strengthen its financial base and secure the funds required for its business development in the fiscal year ending March 2027.